ICU admission was significantly lower in the ivermectin group compared to controls among participants ≥40 year-old (1.2% vs 2.0, odds ratio 0.608; p=0.024).
Similarly, mortality was lower in the ivermectin group in the full group analysis (1.5% vs 2.1%, odds ratio 0.720; p=0.029), as well as in subjects ≥ 40 year- old (2.7% vs 4.1%, odds ratio 0,655; p=0.005).
The May 2021 issue of Antibiotics Review, for example, put out a metanalysis of ivermectin which showed that 100% of 36 prophylaxis and early treatment studies showed positive results, and 26 of the studies showed “statistically significant improvements.”
Medical experts from around the world joined together to present the very latest real world research on repurposing this safe drug that has the ability to transform global efforts to fight the pandemic. Prof. Héctor Carvallo shares his experiences with using ivermectin for long covid in Argentina.
“I am deeply troubled that the WHO made this hasty decision on guidance before reviewing all available data,” said Pierre Kory, MD, MPH, president and chief medical officer of the FLCCC.
“Their recommendation ignores the evidence, creates more controversy, and will only lead to continuing suffering and death from COVID-19. There are now over 24 randomized trials results
that have been reported to the Unitaid/WHO team yet todays guidance was inexcusably based on a faulty analysis of just 16 of the available trials. Further, these erroneous findings directly conflict
with numerous other peer-reviewed expert analyses that have found the data overwhelmingly demonstrates that ivermectin saves lives from COVID-19. There is no reason not to recommend it
for everyone as a safe drug for prevention and treatment.”
The purpose of this study was to assess the effect of oral Ivermectin treatment, which has been associated with iota-carrageenan in repeated doses through the nasal and oral topical route, on the appearance and eventual progression of COVID-19 disease in a healthy population that are exposed to it and have a higher risk of contagion of SARS-COV-2 for being health personnel from
Ivermectin had a significant effect (p=0.003) in achieving medical release. The treatment with ivermectin could significantly prevent the evolution to serious stages since the experimental group did not present any patient with referral to critical hospitalization.
Why is Ivermectin not approved?
Because it does not leave revenue to anyone, it does not generate returns, you cannot make partisan discretion with it, and no one can win an election by applying it, or buy a yacht with its dividends.
Reductions in covid-19 deaths and infections may be possible by using ivermectin. Employing ivermectin early on may reduce the number of people progressing to severe disease. The apparent safety and low cost suggest that ivermectin could have an impact on the SARS-CoV-2 pandemic globally.
The science shows that ivermectin works. Over 40 randomized trials and observational studies from around the world attest to its efficacy against the novel coronavirus. Meta-analyses by four separate research groups, including ours, found an average reduction in mortality of between 68%-75%. And 10 of 13 randomized controlled trials found statistically significant reductions in time to viral clearance, an effect not associated with any other COVID-19 therapeutic. Furthermore, ivermectin has an unparalleled safety record and low cost, which should negate any fears or resistance to immediate adoption.
Ivermectin is an effective treatment for COVID-19. The probability that an ineffective treatment generated results as positive as the 42 studies to date is estimated to be 1 in 4 trillion (p = 0.00000000000023).
Source: Reviews in Cardiovascular Medicine Peter A. McCullough, Paul E. Alexander, Robin Armstrong, Cristian Arvinte, Alan F. Bain, Richard P. Bartlett, Robert L. Berkowitz, Andrew
Source: ivmmeta.com Figure 1. A. Random effects meta-analysis excluding late treatment. Simplified dosages are shown for comparison, these are the total dose in the first two days
Source: Ala Arena In a press conference, the Minister of Health, Mario Kohan, informed that the drug will be used as a treatment against the
Source: HCQMeta.com HCQ is effective for COVID-19 when used early: meta-analysis of 156 studies (Version 28, December 4, 2020) • HCQ is effective for COVID-19.
Hydroxychloroquine (HCQ) appears as an additional therapy, as it possesses immunomodulatory and anti-thrombotic various effects [4-16].
